ADBIOTECH Decides on 7.27 Million Share Third-Party Allotment to Raise 13.26 Billion Won for Operating Funds - 25.9% Discount to Market Price Raises Dilution Concerns
ADBIOTECH decided on a third-party allotment rights offering, issuing 7.27 million new shares at 1,824 KRW each to raise 13.26 billion KRW for operating funds.
The offering represents a massive dilution of approximately 57.5% of the existing 12.66 million shares outstanding, raising concerns about existing shareholder value.
The issue price is at a 2% discount to the reference price of 1,860 KRW, but a 25.9% discount to the current market price of 2,460 KRW, effectively a low-priced issuance.
The allottees are BK Partners Investment Union No. 1, the largest shareholder himself, and Ahn Byung-hwa. BK Partners' ultimate investor, ETRON, received a disclaimer of opinion in its 2025 audit, questioning financial reliability.
The new shares are subject to a one-year lock-up, but repeated amendments to the disclosure indicate schedule delays and uncertainty.
[AI Summary]This rights offering by ADBIOTECH is aimed at raising operating funds, but the massive issuance scale significantly dilutes existing shareholder value, while the disclaimer opinion of the largest shareholder's related entity poses high governance risk. Despite the lock-up protection, the high discount rate could exert downward pressure on the stock price.
KOSDAQ Filing Information
[Correction of Description] Report on Major Events (Decision on Paid-in Capital Increase)